Clarivate Epidemiology’s coverage of CKD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total prevalence of CKD for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the total prevalent patient population, we estimate the number of drug-treatment opportunities in the mature markets.
Clarivate Epidemiology’s CKD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with CKD per year?
In developing countries, what impact will economic growth and development have on the number of people diagnosed with CKD per year?
How will improvements in survival change the number of people living with a diagnosis of CKD?
How will the declining risk of recurrence change the number of people diagnosed with CKD per year?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CKD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following CKD patient populations:
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.
